1. Home
  2. MBAI vs SNSE Comparison

MBAI vs SNSE Comparison

Compare MBAI & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.69

Market Cap

10.1M

Sector

N/A

ML Signal

N/A

Logo Sensei Biotherapeutics Inc.

SNSE

Sensei Biotherapeutics Inc.

HOLD

Current Price

$9.45

Market Cap

10.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBAI
SNSE
Founded
2004
2005
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
10.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MBAI
SNSE
Price
$1.69
$9.45
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$72.50
AVG Volume (30 Days)
539.1K
81.5K
Earning Date
02-08-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.59
$5.00
52 Week High
$3.13
$18.35

Technical Indicators

Market Signals
Indicator
MBAI
SNSE
Relative Strength Index (RSI) N/A 50.75
Support Level N/A $8.50
Resistance Level N/A $9.60
Average True Range (ATR) 0.00 0.74
MACD 0.00 0.11
Stochastic Oscillator 0.00 72.91

Price Performance

Historical Comparison
MBAI
SNSE

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

About SNSE Sensei Biotherapeutics Inc.

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).

Share on Social Networks: